Clinical trial
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin…
NCT00254163 · US Oncology Research, Industry · Completed
Key facts
| NCT number | NCT00254163 |
|---|---|
| Title | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients |
| Official title | A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Astex Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | B-Cell Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Fludarabine, Cyclophosphamide, Rituximab, Pentostatin |
| Enrollment | 184 |
| Start date | Dec 1, 2003 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Nov 15, 2005 |
| Last update posted | Nov 3, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: